References
- Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161:205-14; PMID:25860605; http://dx.doi.org/10.1016/j.cell.2015.03.030
- Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2015; 162(6):1257-70; PMID:26343581; http://dx.doi.org/10.1016/j.cell.2015.08.015
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
- Zelenay S, Reis e Sousa C. Adaptive immunity after cell death. Trends Immunol 2013; 34:329-35; PMID:23608152; http://dx.doi.org/10.1016/j.it.2013.03.005
- Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen Y-S, Shea LK et al. Cancer exome analysis reveals a T-cell-dependent mechanism of csancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx.doi.org/10.1038/nature10755
- DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482:405-9; PMID:22318517; http://dx.doi.org/10.1038/nature10803
- Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160:48-61; PMID:25594174; http://dx.doi.org/10.1016/j.cell.2014.12.033
- Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. Cancer Cell 2009; 15:294-303; PMID:19345328; http://dx.doi.org/10.1016/j.ccr.2009.02.022
- Wang D, Dubois RN. Eicosanoids and cancer. Nature Rev Cancer 2010; 10:181-93; PMID:20168319; http://dx.doi.org/10.1038/nrc2809
- http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2015-10-22-worlds-largest-clinical-trial-on-aspirin-to-stop-cancer-returning-launches-today